Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

The thymus is a crucial training ground for T-cells, the body's "white knights," where they learn to battle the various diseases they may encounter. Thymic function shrinks to nearly nothing as we age ...

Incyte today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 ?

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual ...

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated ...

BPC-157, a pentadecapeptide derived from an endogenously occurring protein sequence in gastric juice, has garnered attention ...

Search for other works by this author on: ...